Contact radiotherapy for rectal cancer treatment
Official title: Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial
Run by Karolinska University Hospital · NCT06501053 · Data updated 2026-11-12
This study is testing a new treatment for early rectal cancer that combines a type of radiation therapy with a shorter course of treatment to see if it can help preserve organs and cause fewer side effects than standard options.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Karolinska University Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Stockholm, Solna and 1 other locations) |
| Status | Recruiting |
| Started | March 3, 2025 |
| Main results expected | April 2030 |
| Study ends | November 2032 |
| Registry record updated | August 10, 2026 |
| Trial ID | NCT06501053 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and above with operable adenocarcinoma of the rectum classified as cT1-cT3ab, N0-N1, and accessible for endocavitary contact X-ray brachytherapy.
✕Probably not a fit
Patients with inoperable rectal cancer, advanced tumor stages, or significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of a combination of Contact x-ray brachytherapy (CXB) and short-course radiotherapy (SCRT) in preserving organs for patients with early and early intermediate rectal cancer. Participants will be randomly assigned to receive either the standard treatment of CXB combined with chemoradiotherapy or the experimental treatment of CXB with SCRT. The primary goal is to determine if the new treatment is non-inferior in terms of the two-year organ preservation rate while potentially reducing side effects compared to existing therapies. This approach is particularly relevant for patients who may not tolerate more intensive treatments.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive option for rectal cancer patients, leading to better organ preservation and fewer side effects.
How similar studies have gone: While previous studies have shown promising outcomes with SCRT and CXB, this specific combination has not been tested in a randomized setting, making it a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adenocarcinoma of the rectum classified as: * cT1-cT3ab, \< 5 cm largest diameter and \< ½ circumference (MRI staging), N0-N1 (\<= 3 nodes \< 8mm diameter), M0 * Performance status (ECOG) 0-1 * Operable patient * Tumor accessible to endocavitary contact X-ray brachytherapy with a distance from the lower tumor border to the anal verge ≤10 cm * 18 years or above * No comorbidity preventing treatment * Patient having read the information note and having signed the informed consent * Follow-up possible Exclusion Criteria: * Inoperable patient * T3cd, T4, T≥ 5cm, Involvement of more than half of the bowel circumference * Distance from the lower tumor border to the anal verge \>10 cm * N2-status at diagnosis or N1 with any node\>= 8 mm diameter * Patient presenting with metastasis at diagnosis (M1) * Previous pelvic irradiation * Tumor with extramural vascular invasion * Poorly differentiated tumor * Simultaneous progressive cancer * Tumor invading external anal sphincter or growth within 1 mm of the levator * Tumor within 1 mm from MRF (mesorectal fascia) * Patient unable to receive CXB or CRT * Any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy * Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol * Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment within 28 days prior to the first dose of study treatment * Total DPD deficiency
Where it's running
-
Karolinska University Hospital, Theme Cancer, Dept of Pelvic cancer
Stockholm, Solna, Sweden Recruiting -
Uppsala University Hospital, Colorectal Surgery
Uppsala, Sweden Recruiting
Study contacts
- Study coordinator: Alexander Valdman, MD, PhD
- Email: alexander.valdman@regionstockholm.se
- Phone: +46 70 002 13 17
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single vs. double stapling and purse-string techniques after rectal cancer surgery
This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Rectal cancer registry to track real-world treatments and outcomes
This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.
-
Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery
This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.
-
Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer
This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.
-
Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer
This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.